Audit: QRS - Oxiracetam for Health & Longevity

Audit conducted on 07/08/2026 19:15 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	91
Passed	81
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	All protocol values, time-to-effect figures, biomarker targets, cadence, benefit/risk tiers, contraindications and interactions trace to ER lines 313–337, 363–389, 422, 448, 450–471.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“rests on no controlled evidence of efficacy in unimpaired adults” and “(caution)” markers carried through verbatim.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Absolute vs. relative renal thresholds and the “(caution)” status of seizure and bipolar-spectrum entries are preserved exactly as in ER lines 331–336.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications come from the ER’s “Populations who should avoid…” list; Key Interactions from the ER interaction bullets; Risks from Potential Risks & Side Effects only.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, NCT identifiers, expert names, or brand names appear anywhere in the QRS.
1.6	The QRS does not introduce new attributions.	🟢	No attributions of any kind are present.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Sober, evidence-weighted register matching the ER Conclusion.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Quantified thresholds paired with plain-language framing; presents what can be measured and acted on.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Declarative statements of what protocols and trials show; no imperatives.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No prescriptive or second-person constructions in the QRS’s own voice.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	E.g. “Split rather than single dosing is standard” states practice rather than instructing.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No occurrences of “you”, “your”, “we”, or “our” in any variable span.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms are limited to biomarker names, which are unavoidable and expanded on first use (eGFR, hs-CRP, ApoB, HbA1c).
2.8	Information is presented in a concise and very compact manner	🟢	Tiered lists are single-clause; protocol sub-cells carry three facts each without elaboration.
2.9	It DOES NOT address the reader directly	🟢	Confirmed by full-text scan; no second-person address.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Self-directed cognitive-enhancement protocol and blinded self-assessment marker address exactly this audience.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Ten-marker baseline panel, 12-week formal cognitive re-testing, and partner-administered blinding assume high willingness.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Optimal functional ranges rather than conventional laboratory cut-offs are used throughout Monitoring.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	At-a-glance foregrounds the impaired-vs-unimpaired split and the supply hazard, which is the decisive point for this audience.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	The string “anti-aging” does not appear; the title uses “Health & Longevity”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	“gastrointestinal disturbance”, “adverse profile”, “estimated glomerular filtration rate”, “non-steroidal anti-inflammatory drug” used throughout.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All present verbatim at lines 446, 494, 547, 577, 597, 637, 666, 670–672, 841 and in the tier <strong> labels.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	71 data-qrs-var spans present, covering every variable named in the checklist (header, at-a-glance, 3 action sets, 3 time sets, 4 benefit tiers, stop/caution items, 4 risk tiers, 10 markers × 3, cadence, 7 qualitative items).
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	The website="evidence_review", website="audit", and website="full_review" spans and the footer disclaimer are untouched.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No ER section mapped into the QRS is empty.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	“Standard approved clinical protocol”, “Self-directed cognitive-enhancement protocol”, “Best time of day”, and all seven qualitative labels match the ER bold labels verbatim.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Biomarker names match the ER table verbatim; benefit and risk items reuse the ER subsection headings.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji characters present; the ER’s “⚠️ Conflicted” markers were correctly dropped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed to the per-section budget: single-clause tier lists, three protocol and three time cells, trimmed interaction parentheticals, one-line biomarker rationales.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14, immediately after <!doctype html> at line 1.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- at line 3, closing --- at line 13.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no duplicate rendering elsewhere.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:03" is quoted, correctly, because it contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	er_filename: oxiracetam_2026-0807-1636_Opus_ER.md at line 4.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	qrs_prompt_version: 26.7.02 matches the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	qrs_creation_date: 2026-0807-1907.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	qrs_creator_ai_nickname: Opus at line 7.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” is a single word with no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	qrs_creator_ai_fullname: Opus 5 at line 8.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	qrs_filename: oxiracetam_2026-0807-1636_Opus_QRS.html matches the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all eight keys; no stray whitespace or unnecessary quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	“Oxiracetam for Health & Longevity - Quick Reference Sheet” at line 22.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	“Oxiracetam for Health & Longevity” at line 417.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	“08/07/2026” from qrs_creation_date: 2026-0807-1907.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	“Opus 5” at line 425.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header contains only the title and the template subline; the ER’s alternate-names line was correctly not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Compresses ER lines 493–497 into the decision-relevant split (impaired vs unimpaired), the untested healthy-adult case, and the supply hazard.
7.2	[at_a_glance] is no longer than 60 words	🟢	59 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	1970s synthetic memory compound (line 493), decades of prescription for damaged brain blood vessels (493), impaired-vs-unimpaired split and never tested in healthy adults (495), safety least contentious and supply hazard with inaccurate labels (497).
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “brain blood vessels” replaces cerebrovascular, “supply” replaces gray market.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial names, years, sample sizes, or p-values.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numeric results of any kind.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All seven items map to the ER’s “Populations who should avoid oxiracetam or use it only with specialist oversight” list (lines 331–337).
8.2	[stop_items] represent the Contraindications from the ER	🟢	All seven ER entries are represented, none added.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Seven <li> elements inside the stop_items span, lines 580–592.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	No dashes introduce trailing clauses; the ER’s mechanistic rationales (“because half-life can extend beyond 24 hours”, “on mechanistic grounds”) were stripped.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	30 and 60 mL/min/1.73 m² thresholds with stage 4–5 / stage 3 staging, the 12-month seizure window, “outside a clinical trial”, and the restricted jurisdictions are all retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in this section.
8.7	If no [stop_items] are present the section is left empty	N/A	Seven stop items are present.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All eight items map to the eight ER interaction bullets at lines 313–327.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All eight ER interaction bullets present; no overlap with the contraindication list.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Eight <li> elements inside the caution_items span, lines 600–627.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Each item is a class name plus its example list; the ER’s “Mitigating action:” and consequence clauses are stripped.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Named drugs retained for the antiepileptic, cholinergic, racetam, stimulant, nephrotoxic, and anticholinergic items; the sedative and supplement lists are trimmed to class or headline agents, not dropped.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in this section.
9.7	If no [caution_items] are present the section is left empty	N/A	Eight caution items are present.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells trace to ER Therapeutic Protocol lines 363–385.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Approved clinical dose, self-directed dose, and timing are the three aspects actionable for this audience; the intravenous hospital and single-enantiomer regimens are correctly excluded as non-transferable.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies more than three actionable aspects; all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	800 mg twice daily / 12 weeks / 2,400 mg ceiling / over-65 adjustment (lines 363, 385); 750–1,500 mg split dosing (line 369); morning and midday with insomnia and tolerance notes (lines 371, 375).

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Measured cognitive effect at 12 weeks, memory effects after a five-day loading period, and arousal at 1–3 hours, all from ER line 422.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Ordered from the High-tier cognitive benefit, through memory effects, to the Low-tier vigilance/arousal effect.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies four distinct time-to-effect aspects; all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	Each sub carries the ER’s own qualifier — premature judgement at two weeks, two-day steady state, and the unreliability of the early subjective impression.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides a dedicated “Time to effect” bullet (line 422).

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All eight benefit headings from ER lines 163–211 are represented in their original tiers.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present and populated, lines 549–570.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each item is the ER subsection heading alone; magnitudes, MMSE and Barthel figures, and funding caveats are all omitted.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses remain; the ER’s “(TBI, …)” expansion and “⚠️ Conflicted” markers were dropped.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four tiers contain items in the ER.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All nine risk headings from ER lines 239–293 are represented in their original tiers.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present and populated, lines 639–660.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each item is the ER subsection heading alone; the canine no-observed-adverse-effect level, half-life ranges, and product-testing percentages are all omitted.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses remain in any risk item.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four tiers contain items in the ER.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Table rows and cadence trace to ER Monitoring Protocol & Defining Success lines 446–461.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All ten ER biomarkers present in ER order: eGFR, cystatin C, serum creatinine, blood urea nitrogen, hs-CRP, ApoB, homocysteine, vitamin B12, HbA1c, ALT/AST, with targets and rationales matching the ER table.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Baseline, 2-week tolerability and sleep check, 12-week kidney and cognitive re-test, 6–12 month follow-up, plus the 3-month interval triggers, all from ER lines 446–448.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All seven items trace to the ER “Qualitative markers” list, lines 463–471.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	Seven of seven listed with the ER’s bold labels verbatim: sleep latency and continuity, headache frequency and timing, sustained attention on demanding work, word-finding and name recall, irritability and restlessness, energy and drive in the afternoon, blinded self-assessment where feasible.

Issues 07/08/2026 19:15

Pass rate 100.00%. No issues found.